GSE160703
Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma
To investigate the effect of cyproheptadine treatment on bladder cancer cells, expression profile was compared in BFTC905 cells treatment DMSO vs 55µM CPH. Overall design: BFTC 905 bladder cancer cells were treated with DMSO (control) or 55µM CPH (treatment).